Ron Winslow calls the annual JPMorgan Healthcare Conference “the biopharmaceutical industry’s annual beginning-of-the-year mating ritual.”
This year is no different.
With the announcement of a research pact between Sanofi-Aventis and the University of California, San Francisco, 2011′s budding relationships seem to be a new breed that unites big pharma and academic research centers.
The language surrounding these new relationships has a lot to do with partnership, collaboration and innovation. True innovation, it has generally been argued, only happens in research institutions where money is given purely for the benefit of human knowledge and discovery. Science focused on financial returns is much more risk-averse, and, as such, limits the creativity of big pharma laboratories.
The Sanofi/UCSF pact specifically runs on two tracks: the first is novel idease and research incubation, and the second focuses on target and drug discovery for cancer and other specific disease spaces.
Elias Zerhouni, Sanofi’s new president of global research and development, further explains the reasoning behind this collaboration in a comment to the WSJ Health Blog, “We have to get close to human biology to understand medicine more than we have in the past.”
Biological inquiry and medical therapy are now closer than they have ever been before.